Clinicians Study brief

GLP-1s & substance use: an emerging signal

Originally posted Mar 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 698 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Reading an observational study in U.S. Veterans with type 2 diabetes.

Could GLP-1 medications help reduce addiction risk?

A new study in The BMJ looked at more than 600,000 U.S. Veterans with type 2 diabetes and reported lower risks of several substance use disorder outcomes among those starting a GLP-1 vs. an SGLT-2 inhibitor.

Over up to 3 years, GLP-1 initiation was associated with a lower risk of new substance use disorder diagnoses across multiple categories. Among Veterans with a pre-existing SUD, GLP-1 initiation was also associated with fewer serious outcomes such as SUD-related ER visits, hospitalizations, overdose, and SUD-related mortality.

Note that this is observational data, so it shows association, not proof of causation. And the population was Veterans with type 2 diabetes, so generalizing it to other groups is still an open question. Also, the relative risk reductions are meaningful, while absolute risk differences vary by outcome.

Still, this is an optimistic signal and it supports the idea that GLP-1s may have effects that extend beyond weight and glycemic control. Now we need well-designed randomized trials.

Check out my infographic for a summary of the findings from the paper.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

GLP-1s & substance use: an emerging signal

Pinch to zoom on touch devices. Open full image ↗